Robert L Coleman
vaniamgroup.com

Robert L Coleman: It’s Time to Normalize Clinical Trial Participation

Robert L Coleman, Gynecologic Oncologist at the Texas Oncology, Chief Medical Officer at Vaniam Group, shared a post on LinkedIn:

“As the Chief Medical Officer at Vaniam Group, I see a persistent and critical challenge, only 7-8% of cancer patients participate in clinical trials. While a lack of available trials is a major barrier, there’s a less visible one – equipping our investigators with the tools to identify and engage patients effectively.

We can’t solve the underrepresentation of patients without addressing the training of the professionals on the front lines. It’s time to normalize clinical trial participation.

What are the biggest barriers to clinical trial participation you’ve observed?”

Robert L Coleman

More posts featuring Robert L Coleman  on OncoDaily.